Search

Your search keyword '"Locatelli, Francesco"' showing total 1,707 results
Start Over Author "Locatelli, Francesco"
1,707 results on '"Locatelli, Francesco"'

4. Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors

Author

Sorin, Boris, Papo, Matthias, Sinico, Renato A., Teixeira, Vítor Silvestre, Venhoff, Nils, Urban, Maria-Letizia, Iudici, Michele, Mahrhold, Juliane, Locatelli, Francesco, Cassone, Giulia, Schiavon, Franco, Seeliger, Benjamin, Neumann, Thomas, Feder, Claudia, Kroegel, Claus, Groh, Matthieu, Marvisi, Chiara, Samson, Maxime, Barba, Thomas, Jayne, David, Troilo, Arianna, Thiel, Jens, Hellmich, Bernhard, Monti, Sara, Montecucco, Carlomaurizio, Salvarani, Carlo, Kahn, Jean-Emmanuel, Bonnotte, Bernard, Durel, Cécile-Audrey, Puéchal, Xavier, Mouthon, Luc, Guillevin, Loïc, Emmi, Giacomo, Vaglio, Augusto, Porcher, Raphael, and Terrier, Benjamin

Published
2024
Full Text
View/download PDF

5. A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence

Author

Bruschi, Maurizio, Angeletti, Andrea, Prunotto, Marco, Meroni, Pier Luigi, Ghiggeri, Gian Marco, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavalli, Andrea, Scapozza, Leonardo, Patel, Jigar J., Tan, John C., Lo, Ken C., Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Giannese, Domenico, Manfredi, Angelo, Ramirez, Giuseppe A., Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Bui, Federica, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisan, Isabella, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Mescia, Federica, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Ravelli, Angelo, Murtas, Corrado, Candiano, Giovanni, Caridi, Gianluca, La Porta, Edoardo, and Verrina, Enrico

Published
2024
Full Text
View/download PDF

6. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Afsar, Baris, Akizawa, Tadao, Anker, Stefan D., Arici, Mustafa, Babitt, Jodie L., Barratt, Jonathan, Berns, Jeffrey S., Besarab, Anatole, Bhandari, Sunil, Brown, Christopher, Cases, Aleix, Chertow, Glenn M., Delgado, Cynthia, Drüeke, Tillman B., Fishbane, Steven, Gómez, Rafael, Grams, Morgan E., Hamano, Takayuki, Hao, Chuan-Ming, Hsu, Raymond K., Iseki, Kunitoshi, Jordans, Isabelle, Lerma, Edgar V., Locatelli, Francesco, Macdougall, Iain C., Małyszko, Jolanta, Maxwell, Patrick, McMahon, Lawrence P., Obrador, Gregorio T., Ostermann, Marlies, Pecoits-Filho, Roberto, Perwad, Farzana, Roger, Simon D., Singh, Ajay K., Solá, Laura, Spinowitz, Bruce S., Sugahara, Mai, Takahashi, Toshiyuki, Tanaka, Mototsugu, Tanaka, Tetsuhiro, Tarng, Der-Cherng, Tonelli, Marcello, Tsukamoto, Yusuke, Walther, Carl P., Yee-Moon Wang, Angela, Kong, Hong, Warady, Bradley A., Webster, Angela C., Weir, Matthew R., Wish, Jay B., Wong, Muh Geot, Ku, Elaine, Del Vecchio, Lucia, Eckardt, Kai-Uwe, Haase, Volker H., Johansen, Kirsten L., Nangaku, Masaomi, Tangri, Navdeep, Waikar, Sushrut S., Więcek, Andrzej, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Wheeler, David C.

Published
2023
Full Text
View/download PDF

9. Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD

Author

Heerspink, Hiddo J.L., Inker, Lesley A., Tighiouart, Hocine, Collier, Willem H., Haaland, Benjamin, Luo, Jiyu, Appel, Gerald B., Chan, Tak Mao, Estacio, Raymond O., Fervenza, Fernando, Floege, Jürgen, Imai, Enyu, Jafar, Tazeen H., Lewis, Julia B., Kam-Tao Li, Philip, Locatelli, Francesco, Maes, Bart D., Perna, Annalisa, Perrone, Ronald D., Praga, Manuel, Schena, Francesco P., Wanner, Christoph, Xie, Di, Greene, Tom, Schrier, Robert W., Hanratty, Rebecca, Maschio, Giuseppe, Carlo, Manno, Saddelli, Mauro, Brenner, Barry M., Lewis, Edmund, von Eynatten, Maximilian, de Jong, Paul E., van Essen, GG, Hou, Fan Fan, Chapman, Arlene, Torres, Vicente, Yu, Alan, Brosnahan, Godela, Chow, Kai-Ming, Szeto, Cheuk-Chun, Leung, Chi-Bon, Hunsicker, Lawrence G., Dwyer, Jamie, Pohl, Marc, Raz, Itamar, Del Vecchio, Lucia, Andrulli, Simeone, Pozzi, Claudio, Casartelli, Donatella, Malfait, Thomas, Vanacker, An, Caravaca-Fontán, Fernando, Trujillo, Hernando, Cavero, Teresa, Gutierrez, Eduardo, Beck, Gerald, Kusek, John, Eknoyan, Garabed, Ponticelli, Claudio, Montagnino, Giuseppe, Passerini, Patrizia, Moroni, Gabriella, Kobayashi, Fumiaki, Makino, Hirofumi, Ito, Sadayoshi, Chan, Juliana CN, Tang, Colin, Gaspari, Flavio, Lesti, Maria Domenica, Gherardi, Giulia, Gamba, Sara, Keane, William, Donadio, James, Rauen, Thomas, Seikrit, Claudia, Wied, Stefanie, Dwyer, Jamie, and Becker, Gavin J.

Published
2023
Full Text
View/download PDF

10. Iron biology.

Author

Vecchio, Lucia Del, Girelli, Domenico, Vinchi, Francesca, Cozzolino, Mario, Elliott, Steve, Mark, Patrick B, Valenti, Luca, Qian, Christopher, Guo, Qian, Qian, Zhong-Ming, Ciceri, Paola, and Locatelli, Francesco

Subjects
RENAL fibrosis, IRON metabolism, CELL metabolism, METABOLIC regulation, CHRONIC kidney failure
Abstract

Iron is a fundamental element for biological life, from bacteria to humans. Iron is essential for cell function and survival, energy production and metabolism, whereas increased levels cause oxidative stress. It is also a constituent of haemoglobin and thus it is necessary for oxygen transportation through the body. Given these multiple functions, the regulation of iron metabolism is complex and tight coupled with oxygen homeostasis at tissue and cellular levels, thanks to the interaction with the hypoxia inducible factor system. In patients with chronic kidney disease (CKD), iron deficiency significantly contributes to anaemia development. This frequently overlaps with chronic inflammation, causing iron- restricted erythropoiesis. To add further complexity, metabolic hyperferritinemia may, on one hand, increase the risk for CKD and, on the other, overlaps with functional iron deficiency. Excessive intracellular iron in certain cell types during CKD can also mediate cellular death (called ferroptosis), and contribute to the pathogenesis of kidney damage, atherosclerosis and vascular calcifications. This review is aimed at broadening the perspective of iron metabolism in the setting of CKD not just as a contributor to anaemia in CKD patients, but also as an important player with an impact on cell metabolism, renal fibrosis and the cardiovascular system. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD

Author

Collier, Willem, Inker, Lesley A., Haaland, Benjamin, Appel, Gerald B., Badve, Sunil V., Caravaca-Fontán, Fernando, Chalmers, John, Floege, Jürgen, Goicoechea, Marian, Imai, Enyu, Jafar, Tazeen H., Lewis, Julia B., Li, Philip K.T., Locatelli, Francesco, Maes, Bart D., Neuen, Brendon L., Perrone, Ronald D., Remuzzi, Giuseppe, Schena, Francesco P., Wanner, Christoph, Heerspink, Hiddo J.L., and Greene, Tom

Published
2023
Full Text
View/download PDF

15. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Author

Abu-Alfa, Ali K., Afsar, Baris, Pai, Amy Barton, Besarab, Anatole, Moore, Geraldine Biddle, Casadevall, Nicole, Cases, Aleix, de Francisco, Angel, Eckardt, Kai-Uwe, Fishbane, Steven, Fried, Linda F., Ganz, Tomas, Ginzburg, Yelena Z., Gómez, Rafael, Goodnough, Lawrence T., Hamano, Takayuki, Hanudel, Mark R., Hao, Chuan-Ming, Iseki, Kunitoshi, Ix, Joachim H., Johansen, Kirsten L., Ketteler, Markus, Kovesdy, Csaba P., Leaf, David E., Macdougall, Iain C., Massy, Ziad A., McMahon, Lawrence P., Minutolo, Roberto, Nakanishi, Takeshi, Nemeth, Elizabeta, Obrador, Gregorio T., Parfrey, Patrick S., Park, Hyeong-Cheon, Pecoits-Filho, Roberto, Robinson, Bruce M., Roger, Simon D., Shah, Yatrik M., Spinowitz, Bruce S., Tanaka, Tetsuhiro, Tsukamoto, Yusuke, Tungsanga, Kriang, Walther, Carl P., Yee-Moon Wang, Angela, Wolf, Myles, Babitt, Jodie L., Eisenga, Michele F., Haase, Volker H., Kshirsagar, Abhijit V., Levin, Adeera, Locatelli, Francesco, Małyszko, Jolanta, Swinkels, Dorine W., Tarng, Der-Cherng, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Drüeke, Tilman B.

Published
2021
Full Text
View/download PDF

16. Evidenze scientifiche: confronto tra gli antipertensivi di uso comune e la Clevidipina. Trials Escape, Eclipse, Pronto, Accelerate, Velocity

Author

Ferdinando L. Lorini, Luigi Tritapepe, Aurora Smeriglia, Dojna Stavri, Claudio Ajmone Cat, Miriam Manera, Giada Bettini, Francesco Daverio, Simone Manocchio, Eleonora Pariani, Marta Ravasi, Alessandro Locatelli, Francesco Zadek, Roberto Fumagalli, Elena Onelli, Federica Di Summa, Manuela Arcoria, Andrea Viscone, Marialuigia Dello Russo, Pietro Valastro, Mario Mezzapesa, Lorini, FL, Zadek, F, Fumagalli, R, Ferdinando L. Lorini, Luigi Tritapepe, Aurora Smeriglia, Dojna Stavri, Claudio Ajmone Cat, Miriam Manera, Giada Bettini, Francesco Daverio, Simone Manocchio, Eleonora Pariani, Marta Ravasi, Alessandro Locatelli, Francesco Zadek, Roberto Fumagalli, Elena Onelli, Federica Di Summa, Manuela Arcoria, Andrea Viscone, Marialuigia Dello Russo, Pietro Valastro, Mario Mezzapesa, Lorini, FL, Zadek, F, and Fumagalli, R

Published
2024

17. Management dello scompenso cardiaco: evidenze dalla letteratura

Author

Ferdinando L. LORINI, Luigi Tritapepe, Aurora Smeriglia, Dojna Stavri, Claudio Ajmone Cat, Miriam Manera, Giada Bettini, Francesco Daverio, Simone Manocchio, Eleonora Pariani, Marta Ravasi, Alessandro Locatelli, Francesco Zadek, Roberto Fumagalli, Elena Onelli, Federica Di Summa, Manuela Arcoria, Andrea Viscone, Marialuigia Dello Russo, Pietro Valastro, Mario Mezzapesa, Lorini, FL, Zadek, F, Fumagalli, R, Ferdinando L. LORINI, Luigi Tritapepe, Aurora Smeriglia, Dojna Stavri, Claudio Ajmone Cat, Miriam Manera, Giada Bettini, Francesco Daverio, Simone Manocchio, Eleonora Pariani, Marta Ravasi, Alessandro Locatelli, Francesco Zadek, Roberto Fumagalli, Elena Onelli, Federica Di Summa, Manuela Arcoria, Andrea Viscone, Marialuigia Dello Russo, Pietro Valastro, Mario Mezzapesa, Lorini, FL, Zadek, F, and Fumagalli, R

Published
2024

18. Results of Tendon Transfers in Radial Nerve Palsies: A New Evaluation Protocol.

Author

Reina, Micaela, Odella, Simonetta, Magnani, Mauro, Locatelli, Francesco, Clemente, Alice, Macrì, Martina, and Tos, Pierluigi

Subjects
RADIAL nerve, PERIPHERAL nerve injuries, FINGER joint, WRIST joint, PATIENT satisfaction
Abstract

Radial nerve palsies present a challenging clinical scenario, often leading to substantial functional impairment. This study focuses on evaluating the outcomes of tendon transfer surgeries in patients with post-traumatic radial nerve injuries. The radial nerve, vital for upper limb movements, faces various etiologies, such as trauma, compression, or idiopathy. Patients with radial nerve palsy encounter difficulties in daily activities, emphasizing the need for effective management strategies. The research introduces a novel evaluation protocol, aiming to comprehensively assess tendon transfer outcomes. This protocol incorporates functional movements of wrist and finger joints, encompassing both objective and subjective parameters. The retrospective study includes eleven patients treated between 2010 and 2022, with a minimum follow-up of one year post-surgery. Tendon transfers demonstrated positive results. The evaluation protocol covers a wide range of parameters, including wrist and finger mobility, thumb function, grip strength, and patient satisfaction. The results indicate successful restoration of motor function, with an average grip strength of 70% compared to the healthy arm. The proposed evaluation protocol facilitates standardized and reproducible assessment, minimizing subjective errors in clinical evaluations. Despite the study's limitations, such as a relatively small sample size, the findings underscore the effectiveness of tendon transfers in treating radial nerve palsies. The introduced evaluation scheme provides a comprehensive and reproducible approach to assess outcomes, contributing to the global standardization of tendon transfer assessments in radial nerve injuries. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Can we effectively manage chronic kidney disease with a precision-based pharmacotherapy plan? Where are we?

Author

Locatelli, Francesco, Paoletti, Ernesto, Ravera, Maura, Pucci Bella, Giulio, and Del Vecchio, Lucia

Subjects
CHRONIC kidney failure, DRUG therapy, INDIVIDUALIZED medicine, AUTOIMMUNE diseases, AUTOANTIBODIES, RITUXIMAB
Abstract

In recent years, thanks to significant advances in basic science and biotechnologies, nephrology has witnessed a deeper understanding of the mechanisms leading to various conditions associated with or causing kidney disease, opening new perspectives for developing specific treatments. These new possibilities have brought increased challenges to physicians, who face with a new complexity in disease characterization and selection the right treatment for individual patients. We chose four therapeutic situations: anaemia in chronic kidney disease (CKD), heart failure in CKD, IgA nephropathy (IgAN) and membranous nephropathy (MN). The literature search was made through PubMed. Anaemia management remains challenging in CKD; a personalized therapeutic approach is often needed. Identifying patients who could benefit from a specific therapy is also an important goal for patients with CKD and heart failure with reduced ejection fraction. Several new treatments are under clinical development for IgAN; interestingly, they target specifically the pathogenetic mechanisms of the disease. The understanding of MN pathogenesis as an autoimmune disease and the discovery of several autoantibodies allows a better characterization of patients. High-sensible techniques for lymphocyte counting open the possibility of more personalized use of anti CD20 therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Dietary Management of Incremental Transition to Dialysis Therapy: Once-Weekly Hemodialysis Combined With Low-Protein Diet

Author

Bolasco, Piergiorgio, Cupisti, Adamasco, Locatelli, Francesco, Caria, Stefania, and Kalantar-Zadeh, Kamyar

Subjects
Kidney Disease, Prevention, Nutrition, Assistive Technology, Bioengineering, Diet, Protein-Restricted, Humans, Kidney Failure, Chronic, Phosphorus, Phosphorus, Dietary, Renal Dialysis, Clinical Sciences, Nutrition and Dietetics, Urology & Nephrology
Abstract

Initiation of thrice-weekly hemodialysis often results in a rapid loss of residual kidney function (RKF) including reduction in urine output. Preserving RKF longer is associated with better outcomes including greater survival in dialysis patients. An alternative approach aimed at preserving RKF is an incremental transition with less frequent hemodialysis sessions at the beginning with gradual increase in hemodialysis frequency over months. In addition to favorable clinical and economic implications, an incremental transition would also enhance a less stressful adaptation of the patient to dialysis therapy. The current guidelines provide only limited recommendations for incremental hemodialysis approach, whereas the potential role of nutritional management of newly transitioned hemodialysis patients is largely overlooked. We have reviewed previous reports and case studies of once-weekly hemodialysis treatment combined with low-protein, low-phosphorus, and normal-to-high-energy diet especially for nondialysis days, whereas on dialysis days, high protein can be provided. Such an adaptive dietary regimen may elicit more favorable outcomes including better preserved RKF, lower β2-microglobulin levels, improved phosphorus control, and lower doses of erythropoiesis-stimulating agents. Clinical and nutritional status and RKF should be closely monitored throughout the transition to once and then twice-weekly regimen and eventually thrice-weekly hemodialysis. Further studies are needed to verify the long-term safety and implications of this approach to dialysis transition.

Published
2016

23. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Author

Macdougall, Iain C, Bircher, Andreas J, Eckardt, Kai-Uwe, Obrador, Gregorio T, Pollock, Carol A, Stenvinkel, Peter, Swinkels, Dorine W, Wanner, Christoph, Weiss, Günter, Chertow, Glenn M, Participants, Conference, Adamson, John W, Akizawa, Tadao, Anker, Stefan D, Auerbach, Michael, Bárány, Peter, Besarab, Anatole, Bhandari, Sunil, Cabantchik, Ioav, Collins, Alan J, Coyne, Daniel W, de Francisco, Ángel LM, Fishbane, Steven, Gaillard, Carlo AJM, Ganz, Tomas, Goldsmith, David J, Hershko, Chaim, Jankowska, Ewa A, Johansen, Kirsten L, Kalantar-Zadeh, Kamyar, Kalra, Philip A, Kasiske, Bertram L, Locatelli, Francesco, Małyszko, Jolanta, Mayer, Gert, McMahon, Lawrence P, Mikhail, Ashraf, Nemeth, Elizabeta, Pai, Amy Barton, Parfrey, Patrick S, Pecoits-Filho, Roberto, Roger, Simon D, Rostoker, Guy, Rottembourg, Jacques, Singh, Ajay K, Slotki, Itzchak, Spinowitz, Bruce S, Tarng, Der-Cherng, Tentori, Francesca, Toblli, Jorge E, Tsukamoto, Yusuke, Vaziri, Nosratola D, Winkelmayer, Wolfgang C, Wheeler, David C, and Zakharova, Elena

Subjects
Hematology, Digestive Diseases, Nutrition, Kidney Disease, Patient Safety, Liver Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Renal and urogenital, Good Health and Well Being, Cardiovascular Diseases, Ferritins, Hematinics, Hemoglobins, Hepcidins, Humans, Hypersensitivity, Infections, Iron, Iron Deficiencies, Iron Overload, Oxidative Stress, Renal Insufficiency, Chronic, chronic kidney disease, hypersensitivity, infections, iron, overload, oxidative stress, Conference Participants, Clinical Sciences, Urology & Nephrology
Abstract

Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.

Published
2016

26. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Author

Sevillano, Angel, Kamper, Anne-Lise, van Zuilen, Arjan D., Brenner, Barry M., Maes, Bart, Ihle, Benno U., Barret, Brendan, Leung, CB, Szeto, CC, Fitzner, Christina, Wanner, Christoph, Pozzi, Claudio, Montagnino, Claudio Ponticelli, Xie, Di, de Zeeuw, Dick, Lewis, Edmund, Verde, Eduardo, Gutierrez, Eduardo, Imai, Enyu, Hou, Fan Fan, Caravaca, Fernando, Fervenza, Fernando C., Locatelli, Francesco, Schena, Francesco Paolo, Kobayashi, Fumiaki, Moroni, Gabriella, Becker, Gavin J., Beck, Gerald J., Appel, Gerald B., Frisch, Gershon, van Essen, GG, Maschio, Giuseppe, Remuzzi, Giuseppe, Montogrino, Giuseppe, Parving, Hans-Henrik, Heerspink, Hiddo J.L., Makino, Hirofumi, Jehan, Imitiaz, Wetzels, Jack F.M., Donadio, James, Dwyer, Jamie, van den Brand, Jan, Kusek, John, Lachin, John M., Luño, Jose, Lewis, Julia B., Floege, Jürgen, Abebe, Kaleab Z., Chow, KM, Hunsicker, Lawrence G., del Vecchio, Lucia, Carlo, Manno, Praga, Manuel, Goicoechea, Marian, von Eynatten, Maximilian, Poulter, Neil, Chaturvedi, Nish, Passerini, Patrizia, de Jong, Paul E., Blankestijn, Peter J., Li, Philip, Ruggenenti, Piero, Zucchelli, Pietro, Kincaid-Smith, Priscilla S., Hilgers, Ralf-Dieter, Estacio, Raymond O., Rohde, Richard D., Katafuchi, Ritsuko, Toto, Robert D., Schrier, Robert W., Rodby, Roger A., Perrone, Ronald D., Ito, Sadayoshi, Klahr, Saulo, Andrulli, Simeone, Strandgaard, Svend, Chan, Tak Mao, Hannedouche, Thierry P., Rauen, Thomas, Greene, Tom, Verdalles, Ursula, Perkovic, Vlado, Keane, William, Heerspink, Hiddo J L, Tighiouart, Hocine, Gansevoort, Ron T, Coresh, Josef, Simon, Andrew L, Lewis, Julia B, Levey, Andrew S, and Inker, Lesley A

Published
2019
Full Text
View/download PDF

27. Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients.

Author

Barrera-Baena, Pedro, Rodríguez-García, Minerva, Rodríguez-Rubio, Enrique, González-Llorente, Lucía, Ortiz, Alberto, Zoccali, Carmine, Locatelli, Francesco, Floege, Jürgen, Cohen-Solal, Martine, Ferreira, Manuel Aníbal, Ketteler, Markus, London, Gerard Michel, Gorriz-Teruel, José Luis, Sánchez-Álvarez, Emilio, Hevia-Suárez, Miguel Ángel, Fernández-Gómez, Jesús María, Martín-Carro, Beatriz, Gómez-Alonso, Carlos, Alonso-Montes, Cristina, and Cannata-Andía, Jorge Benito

Subjects
BONE fractures, RENAL osteodystrophy, PARATHYROIDECTOMY, HEMODIALYSIS patients
Abstract

Background Bone fragility fractures are associated with high morbidity and mortality. This study analysed the association between the current biochemical parameters of chronic kidney disease–mineral and bone disorders (CKD-MBD) and bone fragility fractures in the COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) project. Methods COSMOS is a 3-year, multicentre, open cohort, prospective, observational study carried out in 6797 haemodialysis patients (227 centres from 20 European countries). The association of bone fragility fractures (outcome) with serum calcium, phosphate and parathyroid hormone (PTH) (exposure), was assessed using standard Cox proportional hazards regression and Cox proportional hazards regression for recurrent events. Additional analyses were performed considering all-cause mortality as a competitive event for bone fragility fracture occurrence. Multivariable models were used in all strategies, with the fully adjusted model including a total of 24 variables. Results During a median follow-up of 24 months, 252 (4%) patients experienced at least one bone fragility fracture (incident bone fragility fracture rate 28.5 per 1000 patient-years). In the fractured and non-fractured patients, the percentage of men was 43.7% and 61.4%, mean age 68.1 and 63.8 years and a haemodialysis vintage of 55.9 and 38.3 months, respectively. Baseline serum phosphate >6.1 mg/dL (reference value 4.3–6.1 mg/dL) was significantly associated with a higher bone fragility fracture risk in both regression models {hazard ratio (HR) 1.53 [95% confidence interval (CI) 1.10–2.13] and HR 1.44 (95% CI 1.02–2.05)}. The significant association persisted after competitive risk analysis [subHR 1.42 (95% CI 1.02–1.98)] but the finding was not confirmed when serum phosphate was considered as a continuous variable. Baseline serum calcium showed no association with bone fragility fracture risk in any regression model. Baseline serum PTH >800 pg/mL was significantly associated with a higher bone fragility fracture risk in both regression models, but the association disappeared after a competitive risk analysis. Conclusions Hyperphosphatemia was independently and consistently associated with an increased bone fracture risk, suggesting serum phosphate could be a novel risk factor for bone fractures in haemodialysis patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. List of Contributors

Author

Aghi, Andrea, primary, Akdad, Mourad, additional, Andres, Emmanuel, additional, Bartolini, Desirée, additional, Brandão, Paula, additional, Bridges, Allison, additional, Casanello, Paola, additional, Castaño-Moreno, Erika, additional, Chailyan, S.G., additional, Ciceri, Paola, additional, Conte, Ferruccio, additional, Cozzolino, Mario, additional, Cruciani, Gabriele, additional, Cunningham, John, additional, Dali-Youcef, Nassim, additional, Dalto, Danyel Bueno, additional, Danielyan, K.E., additional, De Santis, Domenica, additional, Dontaraju, Venkata Satish, additional, Dronamraju, Venkateshwara, additional, El Bouhali, Bachir, additional, Emmerson, Joshua T., additional, Fichna, Jakub, additional, Friso, Simonetta, additional, Fusaro, Maria, additional, Galarini, Roberta, additional, Galassi, Andrea, additional, Galli, Francesco, additional, Gallieni, Maurizio, additional, Geier, Andreas, additional, Gioiello, Antimo, additional, Giusepponi, Danilo, additional, Gomes, Cláudio M., additional, Gonçalves, Álisson de Carvalho, additional, Guieu, Samuel, additional, Hagiwara, Shin-ichiro, additional, Hajiluian, Ghazaleh, additional, Henriques, Bárbara J., additional, Iervasi, Giorgio, additional, Jadavji, Nafisa M., additional, Jahn, Daniel, additional, Jankowska, Magdalena, additional, Karmin, O, additional, Kato, Norihisa, additional, Khallouki, Farid, additional, Kruk, Jerzy, additional, Kumrungsee, Thanutchaporn, additional, Labudzinskyi, Dmytro, additional, Laganà, Antonio Simone, additional, Lisakovska, Olha, additional, Llanos, Miguel, additional, Locatelli, Francesco, additional, Marinelli, Rita, additional, Matte, Jean-Jacques, additional, Mazanova, Anna, additional, Mereu, Maria Cristina, additional, Millan-Linares, Maria C., additional, Moftah, Mahira, additional, Montserrat-de la Paz, Sergio, additional, Munirathinam, Gnanasekar, additional, Mustafi, Sushmita, additional, Mutalip, Siti Syairah Mohd, additional, Naranjo, Maria C., additional, Nowicka, Beatrycze, additional, Owen, Robert Wyn, additional, Parkhomenko, Yuliya, additional, Peñailillo, Reyna, additional, Piñuñuri, Raúl, additional, Pizzolo, Francesca, additional, Plebani, Mario, additional, Poirot, Marc, additional, Portari, Guilherme Vannucchi, additional, Prasad, Puttur D., additional, Preedy, Victor R., additional, Price, Mina Yamazaki, additional, Protasova, Zoya, additional, Rajpurohit, Pragya, additional, Rizzo, Gianluca, additional, Ronco, Ana María, additional, Sebastiani, Bartolomeo, additional, Shidfar, Farzad, additional, Shymanskyi, Ihor, additional, Sid, Victoria, additional, Silvente-Poirot, Sandrine, additional, Siow, Yaw L., additional, Siragusa, Lydia, additional, Soldi, Luiz Ricardo, additional, Stucchi, Andrea, additional, Suda, Takashi, additional, Suidasari, Sofya, additional, Sylvester, Paul William, additional, Szymaszkiewicz, Agata, additional, Szymańska, Renata, additional, Thakur, Kiran, additional, Thangaraju, Muthusamy, additional, Tomar, Sudhir Kumar, additional, Torquato, Pierangelo, additional, Trela, Agnieszka, additional, Tripepi, Giovanni, additional, Udali, Silvia, additional, Veliky, Mykola, additional, Vinjamuri, Smita, additional, Vovk, Andriy, additional, Wang, Gaofeng, additional, Wei, Zhao-Jun, additional, Woo, Connie W.H., additional, Yanaka, Noriyuki, additional, Zaninotto, Martina, additional, Zhang, Peipei, additional, and Świerczyński, Mikołaj, additional

Published
2020
Full Text
View/download PDF

33. Erythropoietin in Kidney Disease and Type 2 Diabetes

Author

Locatelli, Francesco, Del Vecchio, Lucia, and Casartelli, Donatella

Subjects
Humans, Kidney Failure, Chronic, Cardiovascular Diseases, Anemia, Diabetes Mellitus, Type 2, Hyperglycemia, Erythropoietin, Hematinics, Darbepoetin alfa, Glycated Hemoglobin, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Published
2011

34. Darbepoetin alfa and chronic kidney disease.

Author

Locatelli, Francesco, Del Vecchio, Lucia, and Casartelli, Donatella

Subjects
Biomedical and Clinical Sciences, Health Sciences, Anemia, Darbepoetin alfa, Diabetes Mellitus, Type 2, Erythropoietin, Female, Hematinics, Hemoglobins, Humans, Iron, Male, Neoplasms, Renal Insufficiency, Chronic, Stroke, Treatment Outcome, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Published
2010

37. Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis

Author

Martín-Carro, Beatriz, primary, Navarro-González, Juan F, additional, Ortiz, Alberto, additional, Zoccali, Carmine, additional, Floege, Jürgen, additional, Ferreira, Manuel A, additional, Gorriz-Teruel, José L, additional, Carrillo-López, Natalia, additional, Panizo, Sara, additional, Locatelli, Francesco, additional, Ketteler, Markus, additional, London, Gerard M, additional, Naves-Díaz, Manuel, additional, Alonso-Montes, Cristina, additional, Cannata-Andía, Jorge B, additional, and Fernández-Martín, José L, additional

Published
2023
Full Text
View/download PDF

40. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

Author

Fellström, Bengt C, Barratt, Jonathan, Cook, Heather, Coppo, Rosanna, Feehally, John, de Fijter, Johan W, Floege, Jürgen, Hetzel, Gerd, Jardine, Alan G, Locatelli, Francesco, Maes, Bart D, Mercer, Alex, Ortiz, Fernanda, Praga, Manuel, Sørensen, Søren S, Tesar, Vladimir, and Del Vecchio, Lucia

Published
2017
Full Text
View/download PDF

41. Unmasking the CONVINCE trial: is hemodiafiltration ready to steal the spotlight in real-world practice?

Author

Meena, Priti and Locatelli, Francesco

Subjects
*HEMODIAFILTRATION, *RENAL replacement therapy, *TREATMENT effectiveness, *QUALITY of life, *MEDICAL personnel, *CARDIOVASCULAR diseases
Abstract

The article explores the use of hemodiafiltration (HDF) as a potential treatment for patients with end-stage kidney disease (ESKD) undergoing kidney replacement therapy. Various studies have been conducted to compare HDF with other dialysis methods, but the results are inconclusive due to differences in study designs and other factors. A meta-analysis found that online hemodiafiltration (OL-HDF) does not significantly improve the quality of life for hemodialysis (HD) patients compared to conventional HD. The CONVINCE trial found that OL-HDF had a lower incidence of death from any cause compared to HD, but there are concerns about the general applicability of the trial's results and the feasibility and cost-effectiveness of OL-HDF in low- and middle-income countries. Further research is needed to confirm the trial's findings and explore the logistics and sustainability of OL-HDF as a treatment option. [Extracted from the article]

Published
2024
Full Text
View/download PDF

42. Hypoxia inducible factor prolyl hydroxylase inhibitors: what a meta-analysis could tell us.

Author

Locatelli, Francesco and Zoccali, Carmine

Subjects
*HYPOXEMIA, *IRON, *HEMODIALYSIS patients, *HEMOGLOBINS, *STATISTICAL significance
Abstract

Meta-analyses offer an estimate of the overall effect size and help address the inconsistency in findings across studies. The risk is the overemphasis on statistical significance while underrepresenting or misinterpreting clinical significance. There's also a lack of standardized methods for quantifying and reporting clinical significance and these measures are often missing or inconsistently reported in many meta-analyses, making it difficult for readers to determine the clinical relevance of the findings. A major merit of Minutolo's meta-analysis is to formally evaluate efficacy and safety of Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHI) as class and as single agents in comparison with ESA, by selecting from only phase-3 randomised clinical trials (RCTs) that compared HIF-PHIs with erythropoiesis-stimulating agents (ESAs) in dialysis and non-dialysis patients. From a clinical perspective, the primary evaluation in this meta-analysis should have been the percentage of patients able to reach and maintain the target haemoglobin (Hb) levels throughout the trials but only a few RCTs selected this primary end point. Any claimed superiority of one drug over another should consider the selected doses. The amount of iron administered to patients, their iron stores and level of inflammation are important confounding factors that affect the reliability of any comparison. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Systemic and targeted steroids for the treatment of IgA nephropathy.

Author

Locatelli, Francesco, Vecchio, Lucia Del, and Ponticelli, Claudio

Subjects
*IGA glomerulonephritis, *CHRONIC kidney failure, *KIDNEY failure, *RANDOMIZED controlled trials, *RENIN-angiotensin system
Abstract

Immunoglobulin A nephropathy (IgAN) is a common glomerulonephritis partially correlated with mucosal immune system dysfunction. Progressive renal failure occurs in many patients, with about 30–50% of the patients with IgAN developing end-stage kidney disease (ESKD). Many treatments have been used for decades, despite uncertainty about their effectiveness and the ideal dose. Randomised controlled trials reported that systemic glucocorticoids can be an effective treatment for patients with persistent and significant proteinuria despite renin-angiotensin system inhibitors use possibly causing systemic side effects. The primary focus of IgAN management should be based on optimised supportive care, including renin-angiotensin system (RAS) blockade and now SGLT2 inhibitors. The novel targeted-release formulation (TRF) of budesonide has been tested to reduce the adverse events of systemic steroids by delivering the drug to the distal ileum. The local efficacy of TRF-budesonide may represent a novel and promising approach to treating IgAN. Two clinical trials showed that TRF-budesonide could significantly reduce proteinuria and haematuria and possibly preserve renal function while significantly reducing the side effects. However, the limited number of treated patients and the relatively short follow-up suggest caution before considering budesonide superior to the current six-months steroid pulses scheme. Long-term data on the efficacy and safety of TRF budesonide are awaited, together with the design of trials with a head-to-head comparison with systemic steroids before considering TRF-budesonide as the standard of care treatment for IgAN nephropathy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Contributors

Author

Albright, Robert C., primary, Amerling, Richard, additional, Angeli, Paolo, additional, Angelotti, Maria Lucia, additional, Antonelli, Massimo, additional, Antoniotti, Riccardo, additional, Arulkumaran, Nishkantha, additional, Asfar, Pierre, additional, Ash, Stephen R., additional, Aucella, Filippo, additional, Aucella, Francesco, additional, Ave, Samuele, additional, Bagshaw, Sean M., additional, Balaraman, Vasanthi, additional, Baldwin, Ian, additional, Bargman, Joanne M., additional, Barletta, Gina-Marie, additional, Barletta, Jeffrey F., additional, Barnela, Shriganesh R., additional, Bayır, Hülya, additional, Beaulieu, Monica, additional, Bellasi, Antonio, additional, Bellomo, Rinaldo, additional, Beloncle, François, additional, Bhansali, Arjun, additional, Bihorac, Azra, additional, Billings, Frederic T., additional, Birk, Horst-Walter, additional, Bonilla-Reséndiz, Luis Ignacio, additional, Bouchard, Josée, additional, Bourke, Edmund, additional, Braitberg, George, additional, Brendolan, Alessandra, additional, Brocca, Alessandra, additional, Brophy, Patrick D., additional, Bucala, Richard, additional, Bunchman, Timothy E., additional, Burdmann, Emmanuel A., additional, Busse, Laurence W., additional, Caires, Renato Antunes, additional, Caironi, Pietro, additional, Camilla, Roberta, additional, Campos, Israel, additional, Canaud, Bernard, additional, Cantaluppi, Vincenzo, additional, Martinez, Maria P., additional, Capasso, Giovambattista, additional, Carcillo, Joseph A., additional, Carlesso, Eleonora, additional, Casino, Francesco G., additional, Castellano, Giuseppe, additional, Catania, Matteo, additional, Cawcutt, Kelly A., additional, Cerda, Jorge, additional, Charen, Elliot, additional, Chawla, Lakhmir S., additional, Chiaramonte, Stefano, additional, Chua, Horng-Ruey, additional, Cianciaruso, Bruno, additional, Ciceri, Paola, additional, Cieslak, Jacek, additional, Clark, William R., additional, Claure-Del Granado, Rolando, additional, Clementi, Anna, additional, Co, Ivan N., additional, Coelho, Fernanda Oliveira, additional, Conte, Ferruccio, additional, Corey, Howard E., additional, Cosmai, Laura, additional, Costalonga, Elerson Carlos, additional, Costamagna, Andrea, additional, Costanzo, Maria Rosa, additional, Cozzolino, Mario, additional, Cramer, Carl H., additional, Cravedi, Paolo, additional, Crepaldi, Carlo, additional, Creteur, Jacques, additional, Crew, R. John, additional, da Costa e Silva, Verônica Torres, additional, Davenport, Andrew, additional, Davies, Andrew R., additional, D'Costa, Rohit, additional, Dean, Dawson F., additional, Debiais, Charlotte, additional, de Cal, Massimo, additional, Dedhia, Paras, additional, de Grooth, Harm-Jan, additional, Dell'Aquila, Roberto, additional, Dellepiane, Sergio, additional, Dellinger, Richard Phillip, additional, Del Vecchio, Lucia, additional, Depner, Thomas A., additional, De Rosa, Silvia, additional, Deutschman, Clifford S., additional, Devarajan, Prasad, additional, Dewitte, A., additional, Di Iorio, Biagio R., additional, Di Lullo, Luca, additional, Di Micco, Lucia, additional, Di Nardo, Matteo, additional, Ding, Xiaoqiang, additional, D'Ippoliti, Fiorella, additional, Di Somma, Salvatore, additional, Doi, Kent, additional, Dries, David J., additional, Druml, Wilfred, additional, Duke, Graeme, additional, Durand, Francois, additional, Eadon, Michael T., additional, Eckstein, Devin, additional, Egi, Moritoki, additional, Eiam-Ong, Somchai, additional, Elbers, Paul W.G., additional, Elli, Francesca, additional, Elliott, Steve, additional, Emlet, David R., additional, Endre, Zoltan, additional, Evans, Roger G., additional, Fanelli, Vito, additional, Fattahi, Fatemeh, additional, Federspiel, Christine Kinggaard, additional, Ferrada, Marcela A., additional, Ferrari, Fiorenza, additional, Fiaccadori, Enrico, additional, Fiorentino, Marco, additional, Fisher, Caleb, additional, Flessner, Michael F., additional, Formica, Marco, additional, Forni, Lui G., additional, Francoz, Claire, additional, French, Craig, additional, Fuhrman, Dana Y., additional, Fumagalli, Giordano, additional, Galbusera, Miriam, additional, Gallieni, Maurizio, additional, Gammill, Hilary S., additional, Gao, Dayong, additional, Garzotto, Francesco, additional, Gatta, Giuseppe, additional, Genga, Kelly R., additional, Genovesi, Simonetta, additional, Genyk, Yuri S., additional, Geradin, Christel, additional, Gesualdo, Loreto, additional, Giavarina, Davide, additional, Giuliani, Anna, additional, Glezerman, Ilya G., additional, Goldstein, Stuart L., additional, Golper, Thomas A., additional, Gómez, Hernando, additional, Granata, Antonio, additional, Grandaliano, Giuseppe, additional, Grasselli, Giacomo, additional, Groeneveld, A.B. Johan, additional, Guerci, Philippe, additional, Gunnerson, Kyle J., additional, Harbord, Nikolas, additional, Harshman, Lyndsay A., additional, Hennessy, Anthony J., additional, Hill, Graham L., additional, Hobson, Charles, additional, Hohenstein, Bernd, additional, Honoré, Patrick M., additional, Horwitz, Edward, additional, Hosseinian, Leila, additional, Hoste, Eric A.J., additional, House, Andrew A., additional, Humes, H. David, additional, Husain-Syed, Faeq, additional, Ince, Can, additional, Ing, Todd S., additional, Jacobs, Rita, additional, Jaswal, Dharmvir, additional, Jeyabalan, Arun, additional, Joannes-Boyau, Olivier, additional, Joannidis, Michael, additional, Joyce, Emily, additional, Kane-Gill, Sandra L., additional, Kaplan, Lewis J., additional, Kashani, Kianoush, additional, Katz, Nevin, additional, Kellum, John A., additional, Khanna, Ramesh, additional, Kim-Campbell, Nahmah, additional, King, Joshua D., additional, Kirwan, Christopher J., additional, Kiss, Joseph E., additional, Klein, David, additional, Kotanko, Peter, additional, Krediet, Raymond T., additional, Kuhlmann, Martin K., additional, Kuiper, Jan Willem, additional, Lachance, Philippe, additional, Lameire, Norbert, additional, Langer, Thomas, additional, Lankadeva, Yugeesh R., additional, Laurin, Louis-Philippe, additional, Lazzeri, Elena, additional, Leblanc, Martine, additional, Lefebvre, Joannie, additional, Lentini, Paolo, additional, Leray-Moragués, Hélène, additional, Levin, Adeera, additional, Lew, Susie Q., additional, Liapis, Helen, additional, Liu, Kathleen D., additional, Livigni, Sergio, additional, Locatelli, Francesco, additional, Lorenzin, Anna, additional, Lu, Jian-Da, additional, Lu, Renhua, additional, Lysak, Nicholas, additional, Macedo, Etienne, additional, Madan, Niti, additional, Madore, François, additional, Maerz, Linda L., additional, Maiden, Matthew J., additional, Malhotra, Rakesh, additional, Marengo, Marita, additional, Mariano, Filippo, additional, Marik, Paul E., additional, Marini, John J., additional, Marino, Rossella, additional, Marshall, Mark R., additional, Mårtensson, Johan, additional, Matsuura, Ryo, additional, May, Clive N., additional, Mazzone, Patrizio, additional, McCauley, Jerry, additional, McCullough, Peter A., additional, McMahon, Blaithin A., additional, Mehta, Ravindra L., additional, Mele, Caterina, additional, Menon, Madhav, additional, Meola, Mario, additional, Mérouani, Aicha, additional, Meuwly, Jean-Yves, additional, Milla, Paola, additional, Misra, Madhukar, additional, Misra, Paraish S., additional, Mizock, Barry A., additional, Modi, Jwalant R., additional, Moeckel, Gilbert, additional, Molitoris, Bruce A., additional, Morabito, Santo, additional, Mucelli, Roberto Pozzi, additional, Murray, Patrick T., additional, Murugan, Raghavan, additional, Nadim, Mitra K., additional, Nair, Devika, additional, Nalesso, Federico, additional, Neri, Mauro, additional, Nguyen, Trung C., additional, Ni, Zhaohui, additional, Noris, Marina, additional, Novick, Tessa, additional, O'Horo, John C., additional, Okusa, Mark Douglas, additional, Opal, Steven M., additional, Opdam, Helen Ingrid, additional, Ostermann, Marlies, additional, Ottaviano, Emerenziana, additional, Oudemans-van Straaten, Heleen M., additional, Overgaard-Steensen, Christian, additional, Padalino, Massimo A., additional, Panichi, Vincenzo, additional, Parameswaran, Priyanka, additional, Patel, Samir S., additional, Payen, Didier, additional, Pea, Federico, additional, Peacock, W. Frank, additional, Peart, Sandrica Young, additional, Peerapornratana, Sadudee, additional, Pelosi, Paolo, additional, Peng, Zhi-Yong, additional, Perico, Norberto, additional, Peruzzi, Licia, additional, Pesce, Francesco, additional, Pesenti, Antonio, additional, Petrucci, Ilaria, additional, Pham, Phuong-Chi, additional, Pham, Phuong-Thu, additional, Phoon, Richard K.S., additional, Piano, Salvatore, additional, Pinsky, Michael R., additional, Piquilloud, Lise, additional, Pistolesi, Valentina, additional, Plank, Lindsay D., additional, Plötz, Frans B., additional, Podestá, Manuel Alfredo, additional, Porta, Camillo, additional, Pozzato, Marco, additional, Prencipe, Michele, additional, Prowle, John R., additional, Puthucheary, Zudin A., additional, Qu, Lirong, additional, Rachoin, Jean-Sebastien, additional, Radhakrishnan, Jai, additional, Ranieri, V. Marco, additional, Ratanarat, Ranistha, additional, Remuzzi, Giuseppe, additional, Resnick, Shelby, additional, Rewa, Oleksa G., additional, Ricci, Zaccaria, additional, Ridel, Christophe, additional, Rifai, Kinan, additional, Ring, Troels, additional, Rizo-Topete, Lilia M., additional, Roessler, Eric, additional, Romagnani, Paola, additional, Romagnoli, Stefano, additional, Ronco, Claudio, additional, Ronco, Federico, additional, Rosner, Mitchell H., additional, Rossetti, Emanuele, additional, Russell, James A., additional, Saab, Georges, additional, Sabatino, Alice, additional, Saboo, Sonali S., additional, Samoni, Sara, additional, Sappington, Penny Lynn, additional, Sartori, Marco, additional, Savige, Judy, additional, Schena, Francesco Paolo, additional, Schneider, Antoine Guillaume, additional, Schraverus, Pieter, additional, Schulte, Wibke, additional, Segoloni, Giuseppe, additional, Semler, Matthew W., additional, Sharma, Aashish, additional, Shaw, Andrew, additional, Sheth, Naitik, additional, Shukla, Ashutosh, additional, Siddall, Eric C., additional, Sievers, Theodore M., additional, Siew, Edward D., additional, Singbartl, Kai, additional, Singer, Mervyn, additional, Singh, Pooja, additional, Smith, Loren E., additional, Soni, Sachin S., additional, Soto, Mara Serrano, additional, Spapen, Herbert D., additional, Srisawat, Nattachai, additional, Srivastava, Ajay, additional, Stellin, Giovanni, additional, Symons, Jordan M., additional, Szamosfalvi, Balazs, additional, Tai, Kian Bun, additional, Takalkar, Unmesh V., additional, Teitelbaum, Isaac, additional, Tetta, Ciro, additional, Thakar, Charuhas V., additional, Tonon, Marta, additional, Trepiccione, Francesco, additional, Triulzi, Darrell, additional, Tushar, Chopra, additional, Uchino, Shigehiko, additional, Valika, Ali, additional, Van Biesen, Wim, additional, Vandenberghe, Wim, additional, Vanholder, Raymond, additional, Vanmassenhove, Jill, additional, Verbine, Anton, additional, Vergano, Marco, additional, Villa, Gianluca, additional, Villeneuve, Pierre-Marc, additional, Vincent, Jean-Louis, additional, Vinsonneau, Christophe, additional, Virzì, Grazia Maria, additional, Visconti, Federico, additional, Visvanathan, Ravindran, additional, Van Vong, Li, additional, Walmrath, Hans-Dieter, additional, Ward, Peter A., additional, Weir, Matthew A., additional, Wen, Xiaoyan, additional, Wendon, Julia, additional, Winchester, James Frank, additional, Wong, Adrian, additional, Woodhouse, Elke L., additional, Xue, Jun, additional, Yadav, Anju, additional, Yerram, Preethi, additional, Yessayan, Lenar, additional, Yeun, Jane Y., additional, Yu, Alex W., additional, Zaccaria, Marta, additional, Zacchia, Miriam, additional, Zachariah, Teena P., additional, Zamperetti, Nereo, additional, Zampieri, Fernando G., additional, Zanco, Pierluigi, additional, Zanella, Alberto, additional, Zanoli, Luca, additional, Zappitelli, Michael, additional, Zaragoza, Jose J., additional, Zarbock, Alexander, additional, Zaroccolo, Marta, additional, Zhang, Han, additional, and Zimmer, Andrea, additional

Published
2019
Full Text
View/download PDF

46. Novel Anemia Therapies in CKD: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Ku, Elaine, primary, Del Vecchio, Lucia, additional, Eckardt, Kai-Uwe, additional, Haase, Volker H., additional, Johansen, Kirsten L., additional, Nangaku, Masaomi, additional, Tangri, Navdeep, additional, Waikar, Sushrut S., additional, Więcek, Andrzej, additional, Cheung, Michael, additional, Jadoul, Michel, additional, Winkelmayer, Wolfgang C., additional, Wheeler, David C., additional, Afsar, Baris, additional, Akizawa, Tadao, additional, Anker, Stefan D., additional, Arici, Mustafa, additional, Babitt, Jodie L., additional, Barratt, Jonathan, additional, Berns, Jeffrey S., additional, Besarab, Anatole, additional, Bhandari, Sunil, additional, Brown, Christopher, additional, Cases, Aleix, additional, Chertow, Glenn M., additional, Delgado, Cynthia, additional, Drüeke, Tillman B., additional, Fishbane, Steven, additional, Gómez, Rafael, additional, Grams, Morgan E., additional, Hamano, Takayuki, additional, Hao, Chuan-Ming, additional, Hsu, Raymond K., additional, Iseki, Kunitoshi, additional, Jordans, Isabelle, additional, Lerma, Edgar V., additional, Locatelli, Francesco, additional, Macdougall, Iain C., additional, Małyszko, Jolanta, additional, Maxwell, Patrick, additional, McMahon, Lawrence P., additional, Obrador, Gregorio T., additional, Ostermann, Marlies, additional, Pecoits-Filho, Roberto, additional, Perwad, Farzana, additional, Roger, Simon D., additional, Singh, Ajay K., additional, Solá, Laura, additional, Spinowitz Mai Sugahara, Bruce S., additional, Takahashi, Toshiyuki, additional, Tanaka, Mototsugu, additional, Tanaka, Tetsuhiro, additional, Tarng, Der-Cherng, additional, Tonelli, Marcello, additional, Tsukamoto, Yusuke, additional, Walther, Carl P., additional, Yee-Moon Wang, Angela, additional, Warady, Bradley A., additional, Webster, Angela C., additional, Weir, Matthew R., additional, Wish, Jay B., additional, and Wong, Muh Geot, additional

Published
2023
Full Text
View/download PDF

47. Change in Albuminuria and GFR Slope as Joint Surrogate Endpoints for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD

Author

Heerspink, Hiddo J.L., primary, Inker, Lesley A., additional, Tighiouart, Hocine, additional, Collier, Willem H., additional, Haaland, Benjamin, additional, Luo, Jiyu, additional, Appel, Gerald B., additional, Chan, Tak Mao, additional, Estacio, Raymond O., additional, Fervenza, Fernando, additional, Floege, Jürgen, additional, Imai, Enyu, additional, Jafar, Tazeen H., additional, Lewis, Julia B., additional, Kam-Tao Li, Philip, additional, Locatelli, Francesco, additional, Maes, Bart D., additional, Perna, Annalisa, additional, Perrone, Ronald D., additional, Praga, Manuel, additional, Schena, Francesco P., additional, Wanner, Christoph, additional, Xie, Di, additional, and Greene, Tom, additional

Published
2023
Full Text
View/download PDF

48. Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis

Author

Inker, Lesley A., Mondal, Hasi, Greene, Tom, Masaschi, Taylor, Locatelli, Francesco, Schena, Francesco P., Katafuchi, Ritsuko, Appel, Gerald B., Maes, Bart D., Li, Philip K., Praga, Manuel, Del Vecchio, Lucia, Andrulli, Simeone, Manno, Carlo, Gutierrez, Eduardo, Mercer, Alex, Carroll, Kevin J., Schmid, Christopher H., and Levey, Andrew S.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results